Thomvest Seed Capital lends $10 mln to ProMetic Life Sciences
Laval, Québec-based biopharmaceutical company ProMetic Life Sciences Inc. (TSX: PLI) has secured a long-term loan in the amount of $10 million from Canadian venture capital firm Thomvest Seed Capital. The company will use part of the proceeds of the investment to commission its cGMP plasma facility and enable the manufacture of plasma-derived orphan drugs starting in the fourth quarter of 2013. Founded in 1994, ProMetic has R&D and manufacturing facilities and business development activities in North America, Europe and Asia.
17 September 2013•5 mins read
